 |
answer text |
<p>The National Institute for Health and Care Excellence (NICE) makes authoritative,
evidence-based recommendations for the National Health Service in England on whether
new licensed medicines should be routinely funded by the NHS, based on an assessment
of their costs and benefits. Decisions on the availability of medicines in Scotland
are a matter for the devolved administration.</p><p>The NICE published guidance in
2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the
treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs
Fund, and it is now available to eligible NHS patients in England in line with the
NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment
of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders
have had an opportunity to appeal against the NICE’s draft recommendations, and the
NICE will consider any appeals through the established process and publish final guidance
in due course.</p>
|
|
